Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma Interventions: Drug: Cyclophosphamide; Drug: Docetaxel; Other: Medical Chart Review; Other: Questionnaire Administration Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma Interventions: Drug: Cyclophosphamide; Drug: Docetaxel; Other: Medical Chart Review; Other: Questionnaire Administration Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition: HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions: Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel; Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor: Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
Conditions: Hormone-receptor-positive Breast Cancer; HER2-low Breast Cancer; HER2-negative Breast Cancer Intervention: Other: No drug Sponsor: Daiichi Sankyo, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition: HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions: Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel; Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor: Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
Conditions: Hormone-receptor-positive Breast Cancer; HER2-low Breast Cancer; HER2-negative Breast Cancer Intervention: Other: No drug Sponsor: Daiichi Sankyo, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition: HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions: Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel; Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor: Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
Conditions: Hormone-receptor-positive Breast Cancer; HER2-low Breast Cancer; HER2-negative Breast Cancer Intervention: Other: No drug Sponsor: Daiichi Sankyo, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition: HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions: Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel; Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor: Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
Conditions: Hormone-receptor-positive Breast Cancer; HER2-low Breast Cancer; HER2-negative Breast Cancer Intervention: Other: No drug Sponsor: Daiichi Sankyo, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials